Perioperative Administration of Gabapentin for Shoulder Arthroscopy: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study

CDR Dennis Spence, CRNA, PhD, NC, USN
LT Jason Goff, CRNA, MSN, NC, USN
LT Erin Mohan, CRNA, MSN, NC, USN
LT Kirsten Bowen, CRNA, MSN, NC, USN
CDR Lisa Osborne, CRNA, PhD, NC, USN
CDR John Maye, CRNA, PhD, NC, USN

Recent studies suggest gabapentin has opioid-sparing effects and may reduce acute postoperative pain. However, there is limited research on the efficacy of gabapentin when combined in a multimodal approach after shoulder arthroscopy under general anesthesia with an interscalene block.

We conducted a prospective, double-blind study of 70 patients who were randomized to receive either 300 mg of gabapentin or placebo 1 hour before surgery, then twice a day for 2 days. The primary outcome was average pain scores. Secondary outcomes included differences in morphine equivalents, adverse effects, and sleep patterns.

No significant differences in pain scores were found on day 1 (gabapentin mean [SD], 4.23 [2.61], vs placebo, 4.61 [2.57]; P = .58) or day 2 (gabapentin, 4.26 [2.39], vs placebo, 4.03 [2.34]; P = .71). Total morphine equivalents on day 1 (gabapentin, 9.75 mg [6.58 mg], vs placebo, 9.52 mg [4.75 mg]; P = .88) and day 2 (gabapentin, 9.21 mg [6.66 mg], vs placebo, 6.93 mg [5.44 mg]; P = .17) were similar. Adverse effects and sleep patterns were similar (P > .05).

These results suggest this dosing regimen of gabapentin is not efficacious in improving outcomes in patients undergoing shoulder arthroscopy under general anesthesia with an interscalene block.

Keywords: Central sensitization, gabapentin, interscalene block, postoperative pain, shoulder arthroscopy.
opioid consumption by 20% to 62%, postoperative pain scores between 18% and 37%, and opioid-related adverse effects. The most frequent adverse effects of gabapentin are sedation and dizziness, which are more common with higher doses, such as 1,200 mg.10

There are limited studies on the perioperative administration of gabapentin after arthroscopic surgery of the shoulder. Adam et al19 investigated the administration of a single preoperative oral dose of 800 mg of gabapentin on postoperative pain and opioid requirements for 48 hours after shoulder arthroscopy surgery with an ISB using 0.5% ropivacaine. In their study, they found no difference in pain or opioid consumption at 24 hours and 48 hours when compared with placebo. It may be that multiday dosing of gabapentin is necessary, because the effect of a single dose of gabapentin may be less than the duration of action of an ISB with ropivacaine, thus leaving patients with substantial pain once the block has worn off.3,6,19

Therefore, the purpose of this investigation was to determine if the perioperative administration of gabapentin for 48 hours is more efficacious than placebo in patients scheduled for arthroscopic shoulder surgery under general endotracheal anesthesia with preoperative placement of an ISB.

Materials and Methods
Following approval from the hospital institutional review board, an experimental, prospective, randomized, double-blind, placebo-controlled study was conducted at a large military training hospital. The study included ASA class 1 and 2 patients 18 to 60 years old scheduled for shoulder arthroscopy surgery under general anesthesia who consented to preoperative placement of an ultrasound-guided ISB. Exclusion criteria were a history of chronic pain syndromes, malignant hyperthermia, neuropathy in the surgical extremity, psychiatric disorders, diagnosed obstructive sleep apnea, or a gabapentin allergy. After informed consent was obtained, patients were randomized by a research pharmacist to an experimental group or a control group using a computer-generated random numbers table. Study medications and randomization sequence were prepared and maintained by the pharmacist. Neither the patient nor the investigators were aware of group assignment. Patients in the experimental group received 300 mg of gabapentin within 1 hour of surgery, followed by 300 mg the night after surgery if able to tolerate oral medications that evening, then 300 mg twice a day for 48 hours. Patients randomized to the control group received identically prepared placebo capsules and were instructed to take the capsules on the exact same regimen as previously described. The investigators wanted to determine the efficacy of this low-dose regimen, because at this facility gabapentin is typically started at 300 mg twice a day and titrated up to minimize adverse effects. Several previous studies13,14,17 have found decreased pain scores with preoperative administration of 300 mg of gabapentin without significant adverse effects.17

Following group assignment, baseline data were obtained, which included demographic information (age, height, weight, body mass index, gender, ethnicity, ASA class, diagnosis, proposed surgical procedure, current medications, and comorbidities), vital signs, and a baseline pain score using a 0 to 10 verbal numeric rating scale (VNRS), in which 0 indicated “no pain” and 10 indicated the “worst possible pain.” All patients then had a peripheral 18-gauge or 20-gauge intravenous (IV) line inserted in the nonoperative extremity and had an infusion of lactated Ringer’s solution started. Before ISB block placement, patients were administered up to 5 mg of midazolam and up to 100 μg of fentanyl. Experienced practitioners then placed an ISB under ultrasound guidance with up to 3 mg/kg (20-30 mL) of 0.5% bupivacaine with 1:400,000 epinephrine. Total local anesthetic volume administered, time to complete block, block success (evaluated as sensory blockade over the operative site before entering the operating room), and complications were recorded on the data collection sheet.

Patients were then transported to the operating room for induction of anesthesia. A standardized anesthetic protocol was used for all patients. Intraoperatively, patients received an IV induction sequence of 1 to 3 μg/kg of fentanyl, up to 1.5 mg/kg of lidocaine, 1 to 2 mg/kg of propofol, and a neuromuscular blocking agent (succinylcholine or rocuronium) at the discretion of the staff anesthesia provider. Anesthesia was maintained with sevoflurane and nitrous oxide or air, and fentanyl titrated by the anesthesia provider. Before extubation, providers administered up to 5 mg neostigmine and 1 mg glycopyrrolate to patients who received rocuronium. After extubation patients were transported to the postanesthesia care unit (PACU). In the PACU, patients could receive up to 500 μg of IV fentanyl for pain, up to 50 mg of IV meperidine for shivering, and 4 mg of ondansetron for postoperative nausea and vomiting. Additional medications were ordered and administered at the discretion of the staff anesthesia provider. Data collection included pain scores using a 0 to 10 VNRS scale, vital signs, Aldrete scores, and neurological scores (level of consciousness, eye opening, best verbal response, and respiratory pattern) on admission and discharge from the PACU. Additional data collection included total opioids administered and total surgical and PACU duration in minutes.

After discharge from the PACU, patients were transported to our same-day surgery unit. When patients met discharge criteria they were discharged to home or admitted overnight and prescribed a combination analgesic (5 mg of oxycodone, and 325 mg of acetaminophen [Percocet]), 1 to 2 tablets every 4 to 6 hours as needed for...
pain. Patients were instructed to take the study medication the night after surgery if possible, then before breakfast and dinner on postoperative days 1 (POD 1) and 2 (POD 2). Patients were given a data collection packet and were contacted by a study investigator on POD 1 and POD 2. Data collection included total sleep duration in hours and sleep quality using a 1 to 5 Likert scale, with 1 indicating they slept “very poorly” and 5 indicating they slept “very well.”21 On the evenings of POD 1 and POD 2, patients were asked to rate their average pain for the day using a 0 to 10 VNRS scale. Patients were also asked to record their average drowsiness and dizziness scores, using a 0 to 10 VNRS scale, with 0 indicating “no drowsiness or dizziness,” to 10 indicating “severe drowsiness or dizziness.” Patients were asked to record whether they took the study medication and total Percocet tablets taken.

Before initiation of the study, a power analysis was performed. Based on previous research, it was hypothesized that patients in the experimental group (gabapentin) would have a mean (SD) pain score value of approximately 45.7 (16).16 Based on the fact that doses of pentadrazine would have a mean (SD) pain score value of approximately 45.7 (16).16 Based on previous research, it was hypothesized that patients in the experimental group (gabapentin) would have a mean (SD) pain score value of approximately 45.7 (16).16 Based on previous research, it was hypothesized that patients in the experimental group (gabapentin) would have a mean (SD) pain score value of approximately 45.7 (16).16 Based on previous research, it was hypothesized that patients in the experimental group (gabapentin) would have a mean (SD) pain score value of approximately 45.7 (16).16 Based on previous research, it was hypothesized that patients in the experimental group (gabapentin) would have a mean (SD) pain score value of approximately 45.7 (16).16 Based on previous research, it was hypothesized that patients in the experimental group (gabapentin) would have a mean (SD) pain score value of approximately 45.7 (16).16

Results

• Sample. A total of 70 patients were enrolled; however, 13 were excluded from the study (experimental group, n = 9 (25.7%); vs control group, n = 4 (11.4%); P = .12) leaving 57 patients for the analysis. Of the 70 patients, 5 were excluded for perioperative events or protocol violation, and 8 were excluded because they did not take the study medication on one or both days. In the gabapentin group, the risk of being excluded from the study was greater (relative risk, 1.52; 95% confidence interval (CI), 0.958-2.40) compared with the control group (relative risk, 0.56; 95% CI, 0.24-1.32; Figure 1).

• Perioperative Data. No significant differences were noted between the 2 groups with regard to baseline demographics or vital signs (P > .05; Table 1). Patients in the gabapentin group did have significantly higher baseline VNRS pain scores; however, an analysis of covariance was completed that indicated baseline pain scores had no significant effect on the primary or secondary outcomes (P > .05). No differences were found between the groups with regard to block volume or success, intraoperative medications, ketorolac use, type of arthroscopic procedure performed, or surgical or PACU duration; PACU admission or discharge Aldrete or neurological scores, vital signs, and PACU morphine equivalents (P > .05; Table 2).

• Primary Outcome. Average pain scores were compared between the 2 groups for POD 1 and POD 2 using a Student t test. A Student t test was used rather than repeated measures analysis of covariance to analyze differences in average pain or opioid consumption, because the time frames for which the data were collected on each day were slightly different. No significant differences were found in average pain scores on POD 1 (experimental group, 4.23 [2.61] vs control group, 4.61 [2.57]; P = .58) and POD 2 (experimental group, 4.26 [2.39], vs control group, 4.03 [2.34]; P = .71) between the 2 groups (Figure 2).

• Secondary Outcomes. Total morphine equivalents were compared between the 2 groups for POD 1 and POD 2 using a Student t test. Total morphine equivalents on POD 1 (experimental group, 9.75 mg [6.58 mg], vs control group, 9.52 mg [4.75 mg]; P = .88) and POD 2 (experimental group, 9.21 mg [6.66 mg], vs control group, 6.93 mg [5.44 mg]; P = .17) were similar (Figure 3).

A χ2 test was used to test the association between group assignment of adverse effect frequency, and a Student t test was used to analyze differences in adverse effect severity. There were no significant differences between the groups in the frequency or severity of the 2 most common adverse effects of gabapentin, dizziness or drowsiness, on POD 1 and POD 2 (P > .05; Table 3). In the gabapentin group, 38.5% of patients reported feeling dizzy compared with 30% in the control group on POD 1 (P = .50). Likewise, the results were similar between the groups on POD 2, with 26.9% of patients in the gabapentin group reporting feeling dizzy compared with 43.3% in the control group (P = .20). On POD 1, 76.9% of patients in the gabapentin group reported feeling drowsy compared with 67.7% in the control group (P = .44). On POD 2, 53.8% of patients in the gabapentin group reported feeling drowsy as compared with 66.7% in the control group (P = .32).

Differences in sleep duration between the 2 groups were compared with a 2-way repeated measures analysis of variance, and in sleep quality using a Mann-Whitney...
Figure 1. Consort Flow Diagram
A per-protocol analysis was conducted. Only patients who took the study medication on both days were included in the final analysis.
Two subjects in the gabapentin group experienced transient intraoperative bradyarythmia events (heart rate decreased from 70-79/min to 20-30/min) requiring treatment with atropine.

<table>
<thead>
<tr>
<th>Demographic variable</th>
<th>Gabapentin group n = 26</th>
<th>Control group n = 31</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>31.8 (10.48)</td>
<td>31.51 (8.9)</td>
<td>.91</td>
</tr>
<tr>
<td>BMI, mean (SD), kg/m²</td>
<td>28.44 (4.02)</td>
<td>28.49 (3.3)</td>
<td>.96</td>
</tr>
<tr>
<td>Gender, no. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>22 (84.6)</td>
<td>26 (83.9)</td>
<td>.62</td>
</tr>
<tr>
<td>Female</td>
<td>4 (15.4)</td>
<td>5 (16.1)</td>
<td></td>
</tr>
<tr>
<td>Ethnicity, no. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>14 (56)</td>
<td>22 (71)</td>
<td>.47</td>
</tr>
<tr>
<td>African American</td>
<td>3 (12)</td>
<td>5 (16.1)</td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>1 (4)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Hispanic, nonwhite</td>
<td>3 (12)</td>
<td>2 (6.5)</td>
<td></td>
</tr>
<tr>
<td>Pacific islander</td>
<td>4 (16)</td>
<td>2 (6.5)</td>
<td></td>
</tr>
<tr>
<td>ASA status, no. (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ASA 1</td>
<td>14 (53.8)</td>
<td>19 (61.3)</td>
<td>.38</td>
</tr>
<tr>
<td>ASA 2</td>
<td>12 (46.2)</td>
<td>12 (38.7)</td>
<td></td>
</tr>
<tr>
<td>Baseline VNRS pain (0-10)</td>
<td>2.61 (2.36)*</td>
<td>1.16 (1.63)</td>
<td>.008</td>
</tr>
</tbody>
</table>

Table 1. Demographics and Baseline Data
*Analysis of covariance results indicated baseline pain score was not a significant covariant in any of the outcomes (P > .05).
Abbreviation: VNRS indicates verbal numeric rating scale.
There were no significant differences in sleep duration between the 2 days ($P = .46$) or between the 2 groups ($P = .051$; see Table 3). Patients in the gabapentin group slept on average 52 minutes longer on both days when compared with the control group. Although sleep duration was slightly longer on both days in the gabapentin group, sleep quality was similar in both groups, with patients in both groups reporting a median score of 4 on a scale of 1 to 5 on both days ($P > .05$).

**Discussion**

Gabapentin has antiallodynic and antihyperalgesic properties that result in decreased central sensitization,\(^7\)\(^,\)\(^10\) which may play a role in acute postoperative pain. Peripheral nerve blocks provide effective postoperative analgesia by blocking peripheral sensitization and may also have an effect on decreasing central sensitization.\(^2\)\(^2\)

The pain scores reported in both groups in the PACU and on POD 1 and POD 2 are consistent with previous research on patients who received an ISB with long-acting local anesthetics.\(^1\)\(^9\) However, as with the previous research study,\(^1\)\(^9\) the negative findings in this study may be related to the effect the ISB had on preventing peripheral and central sensitization, thus masking any clinical effect this gabapentin dosing regimen had on postoperative outcomes. Although our study evaluated a lower preoperative and multiday dosing of gabapentin, the results are consistent with those of Adam et al,\(^1\)\(^9\) who found no significant differences in pain or opioid consumption in 60 patients undergoing shoulder arthroscopy under ISB and general anesthesia randomized to receive a single preoperative dose of 800 mg of gabapentin or placebo. In contrast, Bang et al\(^1\)\(^7\) found a single dose of 300 mg of gabapentin 2 hours before surgery in patients having arthroscopic rotator cuff repair under general anesthesia.
without an ISB had significantly less pain during the first 12 hours after surgery, but not at 24 hours, when compared with placebo. Therefore, it is possible that low-dose gabapentin (300 mg) may have some efficacy in decreasing immediate postoperative pain in patients undergoing shoulder arthroscopy without an ISB.

This is the first study to evaluate multiday administration of gabapentin after shoulder arthroscopy surgery. Our results suggest that 300 mg of gabapentin administered 1 hour before surgery and then twice a day for 48 hours is no more efficacious than placebo on decreasing postoperative pain or opioid consumption in patients undergoing shoulder arthroscopy with ISB (with 0.5% bupivacaine and 1:400,000 epinephrine) and general endotracheal anesthesia. There were no significant differences in the frequency and severity of the most common adverse effects of gabapentin, dizziness and sedation, between the 2 groups. Likewise, sleep quality and duration were similar; however, patients in the gabapentin group slept, on average, 52 minutes longer on both days. The increased sleep duration in the gabapentin group is not surprising given that, clinically, many patients report they sleep longer when taking gabapentin, although in this study, sleep quality was no better than placebo.

There was a trend toward a larger proportion of patients being excluded for perioperative events, attrition, or not taking the study medication in the gabapentin group (25.7% vs 11.4%, \( P = .12 \)). Although not statistically significant, these findings may be clinically relevant. One patient in the gabapentin group withdrew from the study because of medication intolerance. The patient described substantial dizziness and ataxia after taking 2 doses, which is consistent with the adverse effect profile for gabapentin.\(^{10,15}\) In fact, Peng and colleagues\(^{10}\) found the relative risk of dizziness to be 1.4 (95% CI, 1.06-1.84) when compared with placebo. Two patients were excluded in the gabapentin group because they experienced transient intraoperative bradyarrhythmia events. In one case, odansetron was administered before the event and was suspected as contributing to the event. However, in the second case, no odansetron was administered. In both cases, anticholinergics were administered, the events quickly resolved, and the patients were later discharged without complications. Hypotensive and/or bradycardic events have been reported to occur in 29% of patients undergoing shoulder surgery in the sitting position with an ISB and are associated with epinephrine administration (ie, in local anesthetics or irrigation solution).\(^{23}\) The hypotensive and/or bradycardic events have been purported to be mediated by the Bezold-Jarisch reflex.\(^{23}\) Cardiac events have not been previously associated with gabapentin, and both cases were performed in the sitting position. It is possible that these were hypotensive and/or bradycardic events mediated by the Bezold-Jarisch reflex, although we cannot definitively conclude that the gabapentin was not a contributing factor. Sen et al\(^{24}\) reported intraoperative bradycardia occurred in 2 out of 30 patients who received a single dose of 1,200 mg of gabapentin compared with 1 out of 29 patients in the placebo group undergoing inguinal hernia repair under spinal anesthesia (\( P > .05 \)). Cardiac abnormalities, specifically, bradyarrhythmia and asystole, are rare but reported adverse events associated with 5-HT\(_3\) antagonists, including odansetron.\(^{23,26}\)

It is unclear why more patients in the gabapentin group did not take the study medication on one or both days given that reported adverse effects were similar between the 2 groups. In 1 case, the patient (gabapentin group) reported he had trouble swallowing the capsules. It could

<table>
<thead>
<tr>
<th>Adverse effect measure</th>
<th>Gabapentin group n = 26</th>
<th>Control group n = 31</th>
<th>( P ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dizziness, mean (SD), severity (VNRS 0-10)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 1</td>
<td>1.03 (1.88)</td>
<td>0.70 (1.41)</td>
<td>.45</td>
</tr>
<tr>
<td>Day 2</td>
<td>0.65 (1.26)</td>
<td>1.26 (1.91)</td>
<td>.15</td>
</tr>
<tr>
<td>Drowsiness, mean (SD), severity (VNRS 0-10)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 1</td>
<td>3.65 (2.91)</td>
<td>3.09 (2.88)</td>
<td>.48</td>
</tr>
<tr>
<td>Day 2</td>
<td>1.69 (2.22)</td>
<td>2.90 (2.85)</td>
<td>.10</td>
</tr>
<tr>
<td>Sleep duration, mean (SD), h</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 1</td>
<td>7.44 (1.91)</td>
<td>6.48 (2.55)</td>
<td>.12</td>
</tr>
<tr>
<td>Day 2</td>
<td>7.55 (1.95)</td>
<td>6.76 (2.53)</td>
<td>.21</td>
</tr>
<tr>
<td>Sleep quality, median (minimum, maximum),</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(1, very poor to 5, very well)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 1</td>
<td>4 (1, 5)</td>
<td>4 (2, 5)</td>
<td>.85</td>
</tr>
<tr>
<td>Day 2</td>
<td>4 (1, 5)</td>
<td>4 (1, 5)</td>
<td>.30</td>
</tr>
</tbody>
</table>

Table 3. Secondary Outcomes
Abbreviation: VNRS indicates verbal numeric rating scale.
be that asking patients who are recovering from surgery to take an additional medication, such as gabapentin twice a day for 48 hours, increases patient burden and decreases adherence to the dosing regimen. This is especially true when the patients are unsure whether the medication is going contribute to their analgesic regimen.\(^\text{27}\) Patient withdrawal due to adverse effects of dizziness and sedation has been reported in previous studies evaluating the efficacy of multiday dosing regimens of gabapentin.\(^\text{18}\) Given the excellent postoperative analgesia provided by the ISB and the lack of differences in efficacy, it is possible that in some patients the adverse effects and/or increased burden of taking a medication to which they are not accustomed may have contributed to decreased adherence. The patients in this investigation were a predominately young, male, active duty military population, and thus may differ from previous populations studied.\(^\text{19}\)

Although gabapentin has demonstrated efficacy in multiple surgical populations,\(^\text{10}\) there is still a paucity of studies on the efficacy of multiday dosing. Kong and Irwin\(^\text{28}\) in their systematic review and meta-analysis, reported that only 4 out of 16 perioperative randomized placebo-controlled trials of gabapentin evaluated multiday dosing, all with conflicting results. They concluded that multiday dosing of gabapentin offered no benefit over single-day dosing. As was demonstrated in this current study, adherence with multiday dosing of gabapentin is difficult. As a result, the conflicting results reported by Kong and Irwin\(^\text{28}\) could be related to decreased adherence. Given the limited number of studies and the fact that gabapentin has shown some efficacy in decreasing postoperative pain,\(^\text{29}\) future research should focus on multiday dosing,\(^\text{30}\) consider objective measures for monitoring and improving adherence (eg, medication event monitors),\(^\text{31}\) and report both the frequency and severity of adverse effects.\(^\text{32}\)

Most of the research on gabapentin reports only the frequency of adverse effects (ie, dizziness and sedation), rather than the frequency and severity. Reporting of adverse effect severity is important to anesthesia providers because this allows them to analyze the risk-benefit profile to determine if a medication such as gabapentin will provide benefit to a patient. This study was one of the few to evaluate severity of the most common adverse effects, dizziness and sedation. Dierking et al\(^\text{32}\) used a Likert scale to evaluate somnolence severity, but only reported the frequency of dizziness in 80 patients undergoing abdominal hysterectomy randomized to receive 1,200 mg of oral gabapentin or placebo 1 hour before surgery, followed by 600 mg of oral gabapentin or placebo 8, 16, and 24 hours after the initial dose. Similar to these findings, no significant differences were noted between the groups in the severity of somnolence and the frequency of dizziness by Dierking et al.\(^\text{32}\) However, they did state that residual effects of anesthetic agents and surgery may have masked adverse effects from gabapentin. Investigators should consider these issues when designing future studies.

There are several limitations of this study. First, some patients may have taken their pain medications around the clock instead of as needed, which could account for the lack of group differences. In addition, the dosing strategy for gabapentin may have been too low to achieve a clinical effect.\(^\text{28}\) Peng et al\(^\text{10}\) reported in their meta-analysis that there was no benefit in starting a dose greater than 600 mg, whereas Kong and Irwin\(^\text{28}\) recommended administering a single preoperative dose of less than or equal to 1,200 mg to minimize adverse effects. Rusy et al\(^\text{18}\) found that initial dosages of 15 mg/kg followed by 5 mg/kg 3 times per day for 5 days were associated with significantly less postoperative pain and opioid consumption in the pediatric population undergoing spinal fusion surgery. Relating this information to our study, if our patients had an average weight of 70 kg, this would equilibrate to an initial gabapentin dose of 1,050 mg, which would be within the range recommended by Peng et al\(^\text{10}\) and Irwin and Kong.\(^\text{28}\) Perhaps the 300-mg dosage administered twice-a-day in this study was too low, especially considering the patients received an ISB. Gabapentin has a half-life of 6.5 hours, so it is possible that the patients’ pain perceptions were higher in the middle of the day when plasma levels were lower. However, at our facility, gabapentin is typically started at 300 mg twice a day and titrated up to avoid excessive dizziness and sedation. We felt this was an appropriate dose to evaluate because it reflected our clinical practice. To compensate for the less frequent dosing regimen, we evaluated average pain and total opioid consumption on each day, rather than pain at specific times of the day or with activity.

**Conclusion**

Gabapentin has demonstrated efficacy as a single preoperative dose in multiple surgical populations.\(^\text{10}\) Nevertheless, given the lack of efficacy, potential adverse reactions, adverse effects, and nonadherence issues in this current study, we would not recommend this dosing regimen of gabapentin for shoulder arthroscopy with general anesthesia and interscalene block with long-acting local anesthetics. Future studies are needed on the effect of single-day and multiday gabapentin regimens on postoperative pain and should incorporate measures of adverse effect severity and include objective measures of adherence.

**REFERENCES**

4. Fredrickson MJ, Krishnan S, Chen CY. Postoperative analgesia for


AUTHORS

CDR Dennis Spence, CRNA, PhD, NC, USN, is the Phase II clinical research director and assistant professor, Uniformed Services University of the Health Sciences, Graduate School of Nursing, Nurse Anesthesia Program, at Naval Medical Center San Diego, California. Email: dennis.spence@med.navy.mil

LT Jason Goff, CRNA, MSN, NC, USN,* is a staff nurse anesthetist at Naval Medical Center San Diego, California.

LT Erin Mohan, CRNA, MSN, NC, USN,* is a staff nurse anesthetist at Naval Hospital Okinowa, Japan.

LT Kirsten Bowen, CRNA, MSN, NC, USN,* is a staff nurse anesthetist at Naval Medical Center San Diego, California.

CDR Lisa Osborne, CRNA, PhD, NC, USN, is the research director and assistant professor in the Uniformed Services University of the Health Sciences, Graduate School of Nursing, Nurse Anesthesia Program in Bethesda, Maryland.

CDR John Maye, CRNA, PhD, NC, USN, is director of the Triservice Nursing Research Program. At the time this article was written he was the research director and associate professor in the Uniformed Services University of the Health Sciences, Graduate School of Nursing, Nurse Anesthesia Program in Bethesda, Maryland.

*At the time this article was written, these authors were students in the Uniformed Services University of the Health Sciences, Graduate School of Nursing, Nurse Anesthesia Program, Naval Medical Center San Diego.

ACKNOWLEDGMENT

The investigators would like to thank Deedee Watts, RN, PhD, for assistance in the statistical analyses and LT Kevin Wong, BSN, NC, USN, for assistance on this project.

DISCLAIMER

The views expressed in this article are those of the authors and do not reflect official policy or position of the Department of the Navy, Uniformed Services University of the Health Sciences, Department of Defense, or the United States Government.